Endocrine dysfunction in Prader-Willi syndrome: A review with special reference to GH

Endocrine Reviews

Volumn 22, Issue 6, 2001, Pages 787-799

  Burman, Pia ^a   Ritzén, E Martin ^b   Lindgren, Ann Christin ^b  

^a Pharmacia Corporation   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; SEX HORMONE; TESTOSTERONE;

APPETITE DISORDER; BEHAVIOR DISORDER; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ENDOCRINE DISEASE; FACE DYSMORPHIA; GENETIC DISORDER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HUMAN; HYPOGONADOTROPIC HYPOGONADISM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; INCIDENCE; LEAN BODY WEIGHT; LONG TERM CARE; LUNG FUNCTION; MENTAL DEFICIENCY; MORBIDITY; MORTALITY; MUSCLE HYPOTONIA; OBESITY; PHYSICAL ACTIVITY; PRADER WILLI SYNDROME; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SHORT STATURE;

EID: 0035719948     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/edrv.22.6.0447     Document Type: Review

References (119)

1. Ein syndrome von adipositas, kleinwuchs, kryptorchismus und oligophrenie nach myotonieartigem zustand im neugeborenenalter
2. Das syndrom yon imbezilliat, adipositas muskelhypotonie, hypogenitalismus und diabetes mellitus mit "myatonic"-anamnese
3. Genetic and clinical advances in Prader-Willi syndrome
4. Prader-Willi syndrome
5. Genetic abnormalities in Prader-Willi syndrome and lessons from mouse models
6. Imprinting in Prader-Willi and Angelman syndromes
7. Prader-Willi syndrome
8. Prader-Willi syndrome. Consensus diagnostic criteria
9. The Prader-Willi syndrome. A study of 40 patients and a review of the literature
10. Prevalence study of Prader-Willi syndrome in North Dakota
11. Frequency of the Prader-Willi syndrome in the San-in district, Japan
12. DNA methylation based testing of 450 patients suspected of having Prader-Willi syndrome
13. Imprinting mutations on human chromosome 15
14. Prader-Willi syndrome
15. Peculiar body composition in patients with Prader-Labhart-Willi syndrome
16. Reference values for height and weight in Prader-Willi syndrome based on 315 patients
17. Prader-Willi syndrome
18. Energy expenditure and body composition in Prader-Willi syndrome
19. Assessment of body composition in Prader-Lubhart-Willi syndrome
20. Adults with Prader-Willi syndrome. A survey of 232 cases
21. Prader-Willi syndrome after the age of 15 years
22. Standards for selected anthropometric measurements in Prader-Willi syndrome
23. Spontaneous growth in German children and adolescents with genetically confirmed Prader-Willi syndrome
24. Standard growth curves for Japanese patients with Prader-Willi syndrome
25. Prader-Willi syndrome. Genetic, behavioral, and treatment issues
26. Prader-Willi syndrome: A review with special attention to cognitive and behavioral profile
27. Assessment of body composition in the Prader-Willi syndrome using bioelectrical impedance
28. Using stable isotopes to assess reduced physical activity of individuals with Prader-Willi syndrome
29. Body composition studies in Prader-Willi syndrome: Effects of growth hormone therapy
30. Determinants of body composition measured by dual-energy x-ray absorptiometry in Dutch children and adolescents
31. Body composition assessment by dual-energy x-ray absorptiometry in subjects aged 4-26
32. Body fat determined by skinfold measurements is elevated despite underweight in infants with Prader-Labhart-Willi syndrome
33. Activity levels of persons with Prader-Willi syndrome
34. Outpatient dietary management in the Prader-Willi syndrome
35. Physiology and natural history of obesity
36. Activity related energy expenditure in children and adolescents with Prader-Willi syndrome
37. Energy expenditure at rest and during sleep in children with Prader-Willi syndrome is explained by body composition
38. Childhood obesity: Pathophysiology and treatment
39. Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality. A prospective population study
40. Presence of metabolic cardiovascular syndrome in obese children
41. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: Results from the Swedish Obese Subjects study
42. Overweight, obesity and health risk
43. Prader-Willi syndrome and scoliosis
44. Endocrine and metabolic aspects of Prader-Willi syndrome
45. The endocrine profiles and metabolic aspects of Prader-Willi syndrome
46. A reduced number of insulin receptors in patients with Prader-Willi syndrome
47. Glucose intolerance and diabetes mellitus in patients with the Prader-Labhart-Willi syndrome
48. Aging in Prader-Willi syndrome: 22 Patients over age 30 years
49. Low insulin, IGF-I and IGFBP-3 levels in children with Prader-Labhart-Willi syndrome
50. Growth hormone treatment of children with Prader-Willi syndrome: Effects on glucose and insulin hemostasis
51. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy
52. Characterization of alterations in glucose and insulin metabolism in Prader-Willi subjects
53. Acantosis nigricans in association with various genodermatosis
54. Premature coronary artery atherosclerosis in a patient with Prader-Willi syndrome
55. Prader-Willi syndrome
56. Hyperlipidemia, insulin-dependent diabetes mellitus, and rapidly progressive diabetic retinopathy and neuropathy in Prader-Willi syndrome with del. (15) (q11.2q13)
57. Hypotonia, mental retardation, obesity, and cryptorchidism associated with dwarfism, and diabetes in children
58. The Prader-Willi syndrome, regulation of fat transport
59. Fasting plasma lipid, glucose, and insulin levels in Prader-Willi syndrome and obese individuals
60. Growth hormone improves body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome: A controlled study
61. Cardiovascular risk factors improve during 3 years of growth hormone therapy in Prader-Willi syndrome
62. Pulmonary function abnormalities in Prader-Willi syndrome
63. Arousal and cardiorespiratory responses to hypoxia in Prader-Willi syndrome
64. Respiratory control in children with Prader-Willi syndrome
65. Growth hormone treatment increases CO(2)-response, ventilation and central respiratory drive in children with Prader-Willi syndrome
66. Untersuchungen beim Prader-Labhart-Willi-syndrome
67. Growth hormone secretion in Prader-Willi syndrome
68. Studio endocrino nella sindrome di Prader-Willi. A proposito di 5 casi
69. Endocrine status, growth hormone therapy and body composition in Prader-Willi syndrome
70. Growth hormone (GH) response to combined pyridostigmine and GH-releasing hormone administration in patients with Prader-Labhardt-Willi syndrome
71. Growth hormone secretion and effects of growth hormone therapy on growth velocity and weight gain in children with Prader-Willi syndrome
72. Growth hormone secretion in Prader-Willi syndrome
73. Reduced growth hormone (GH) responsiveness to combined GH-releasing hormone and pyridostimine and administration in the Prader-Willi syndrome
74. Growth hormone treatment of children with Prader-Willi syndrome affects linear growth and body composition favourably
75. Growth hormone therapy in children with Prader-Willi syndrome. A preliminary report of one year treatment in 19 children
76. Growth failure in Prader-Willi syndrome is secondary to growth hormone deficiency
77. GH/IGF-I axis in Prader-Willi syndrome: Evaluation of IGF-I levels and of the somatotroph responsiveness to various provocative stimuli
78. Impairment of GH responsiveness to GH-releasing hexapeptide (GHRP-6) in Prader-Willi syndrome
79. Impaired growth hormone responses to growth hormone-releasing factor In obesity: A pituitary defect reversed by weight reduction
80. Growth hormone in obesity
81. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects
82. Effect of obesity on total and free insulin-like growth factor (IGF)-I, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone
83. Serum levels of insulin-like growth factor (IGF)-I, free IGF-I, IGF binding protein (IGFBP)-1, IGFBP-3 and insulin in obese children
84. Effect of cholinergic enhancement by pyridostigmine on growth hormone secretion in obese adults and children
85. Impairment of GH responsiveness to GH releasing hormone and pyridostigmine in patients affected with Prader-Labhardt-Willi syndrome
86. Serum levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in obese children
87. Growth hormone bioactivity, insulin-like growth factors (IGFs) and IGF binding proteins in obese children
88. Effects of systemic (GH) administration on regional adipose tissue distribution in GH deficient children
89. Growth and development in simple obesity
90. The effect of simple obesity on growth and growth hormone
91. Alterations in the hypothalamic paraventricular nucleus and its oxytocin neurones (putative satiety cells) in Prader-Willi syndrome. A study of five cases
92. Prader-Willi syndrome and the hypothalamus
93. MR of the pituitary in patients with Prader-Willi syndrome: Size determinations and imaging findings
94. Prader-Labhart-Willi syndrome: Auxological response to a conventional dose of growth hormone in patients with classical growth hormone deficiency
95. Pubertal development in the Prader-Labhart-Willi syndrome
96. Precocious puberty in a male with Prader-Labhart-Willi syndrome
97. Primary gonadal failure and precocious adrenarche in a boy with Prader-Labhart-Willi syndrome
98. Endocrine function in the Prader-Willi syndrome
99. Endocrine physiology and therapy in Prader-Willi syndrome
100. Anterior pituitary function in the Prader-Labhart-Willi syndrome
101. Hypogonadism in Prader-Willi syndrome
102. Absence of spermatogonia in the Prader-Willi syndrome
103. A women with Prader-Willi syndrome gives birth to a healthy baby girl
104. Fertility in Prader-Willi syndrome: A case report with Angelman syndrome in the offspring
105. Adrenal response to ACTH in patients with Prader-Willi syndrome, simple obesity, and constitutional dwarfism
106. Steroid metabolic disturbances in Prader-Willi syndrome
107. Premature adrenarche, increased growth velocity and accelerated bone age in male patients with Prader-Labhart-Willi syndrome
108. Dietary intervention in the first four years prevents abnormal weight gain but negatively affects height development in Prader-Willi syndrome
109. Effects of growth hormone treatment on growth and body composition in Prader-Willi syndrome: A preliminary report
110. One-year results of growth hormone treatment of short stature in Prader-Willi syndrome
111. Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome
112. Treatment with human growth hormone in patients with Prader-Labhart-Willi syndrome reduces body fat and increases muscle mass and physical performance
113. Five years of growth hormone treatment in children with Prader-Willi syndrome
114. Growth hormone normalizes height, prediction of final height and hand length in children with Prader-Willi syndrome after 4 years of therapy
115. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome
116. Body composition abnormalities in children with Prader-Willi syndrome and long-term effects of growth hormone therapy
117. Auxological and endocrine evolution of 28 children with Prader-Willi syndrome: Effect of GH therapy in 14 children
118. Hypogonadism and osteoporosis